Clinical Trial Update: Prospective Evaluation for Receiving SynFlow 3.0 Interventional Circulatory Support in High-risk PCI: A Randomized Controlled Trial [NA]

View source ↗

Summary

This clinical trial update notes the completion of a randomized controlled evaluation of SynFlow 3.0 Interventional Circulatory Support in high-risk percutaneou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• SynFlow 3.0 Interventional Circulatory Support

Snippet

Sponsor: ForQaly Medical (Shanghai) Co., Ltd | Conditions: High Risk PCI, Coronary Arterial Disease (CAD) | NA | Status: COMPLETED